General characteristics of survey participants, Morocco 2011.

a<p>ORS: Observatoire Régional de Santé;</p>b<p>CPE: Cellule Provinciale ou Préfectorale d'Epidémiologie;</p>c<p>Other basic qualifications (in decreasing frequency): engineer, hygiene technician, administrator, biologist.</p

Level of self-estimated competence in each area, by basic qualification, Morocco 2011.

<p>Level of self-estimated competence in each area, by basic qualification, Morocco 2011.</p

Comparison of several two-steps (6 and 12 months) algorithms for early outcome determination.

a<p>As reported by Mumba 2010, “algorithm C”: includes deaths as treatment failures and patients with incomplete follow-up;</p>b<p>Same algorithm tested with our dataset including only laboratory-confirmed outcomes. LR: Likelihood ratio. False cured: fraction of patients that are wrongly classified as cured by the algorithm.</p

Competence gap (self-rated), by basic qualification.

<p>Gap between the importance given to surveillance tasks (grouped in 10 broad areas) and the self- estimated competence (rated by each participant using a scale of 1 to 9), by basic qualification categories.</p

Preparation of a nifurtimox-eflornithine combination therapy (NECT) kit at MSF-Logistique, Mérignac, France.

<p>Photo credit: V. Carlier/MSF-Logistique.</p

List of 33 tasks surveyed (original text in French), and their grouping in 10 domains.

<p>List of 33 tasks surveyed (original text in French), and their grouping in 10 domains.</p

Importance attributed to surveillance tasks (grouped in 10 domains), by basic qualification, Morocco 2011.

<p>Importance attributed to surveillance tasks (grouped in 10 domains), by basic qualification, Morocco 2011.</p

Baseline characteristics of patients included in each analysis.

<p>First analysis: leukocytes at 6 months, excluding relapses at 6 months; Second analysis: leukocytes at 6 months, including relapses at 6 months, two-step algorithms. Combination treatment: within this selected cohort, it included melarsoprol-eflornithine, nifurtimox-eflornithine and melarsoprol-nifurtimox combinations. Coma score: Glasgow Coma Scale assessing the level of consciousness. Interpretation: 3–8 = severe impairment; 9–12 = moderate impairment; 13–14 = mild impairment; 15 = normal <a href="http://www.plosntds.org/article/info:doi/10.1371/journal.pntd.0001662#pntd.0001662-Teasdale1" target="_blank">[13]</a>; Karnofsky index <a href="http://www.plosntds.org/article/info:doi/10.1371/journal.pntd.0001662#pntd.0001662-Mor1" target="_blank">[14]</a>.</p

Study profile: selection of study patients.

<p>Patients from 12 Médecins Sans Frontières sites in Uganda, Sudan, Angola, Central African Republic, Republic of Congo and Democratic Republic of Congo, 1995–2006. ^a Among these 906 exclusions there are 125 patients that relapsed before 6 months (hence falling out of the scope of this study); ^b Tolerance window up to 9 months.</p

Evolution of the CSF leucocytes count by final treatment outcome, by treatment group and overall.

<p>CSF leucocytes count expressed as the median and interquartile range (IQR). Cohort of 1822 patients having a leukocytes count performed at 6 months and not relapsing at 6 months or earlier, who had a complete follow-up. Values at month 0 are pre-treatment measurements. The number of patients per group is shown at each time point. Dotted lines are used to signify that samples over time contain some different patients.</p